Barclays PLC Evolus, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Evolus, Inc. stock. As of the latest transaction made, Barclays PLC holds 93,662 shares of EOLS stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

93,662

Previous 93,662 -0.0%

Holding current value

$1.02 Million

Previous $1.52 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$10.66 - $17.48 $727,150 - $1.19 Million	68,213 Added 268.04%	93,662 $1.52 Million
Q2 2024 Aug 14, 2024	SELL	$10.45 - $13.76 $179,092 - $235,818	-17,138 Reduced 40.24%	25,449 $276,000
Q1 2024 May 15, 2024	SELL	$9.99 - $14.91 $268,431 - $400,631	-26,870 Reduced 38.69%	42,587 $595,000
Q4 2023 Feb 15, 2024	BUY	$7.6 - $10.53 $377,438 - $522,951	49,663 Added 250.9%	69,457 $730,000
Q3 2023 Nov 07, 2023	BUY	$7.15 - $10.2 $27,806 - $39,667	3,889 Added 24.45%	19,794 $181,000
Q2 2023 Aug 03, 2023	SELL	$7.23 - $10.52 $14,929 - $21,723	-2,065 Reduced 11.49%	15,905 $115,000
Q1 2023 May 04, 2023	BUY	$7.81 - $11.05 $66,080 - $93,494	8,461 Added 88.98%	17,970 $152,000
Q4 2022 Feb 13, 2023	SELL	$6.52 - $8.95 $2,757 - $3,785	-423 Reduced 4.26%	9,509 $72,000
Q3 2022 Nov 03, 2022	SELL	$7.76 - $13.72 $105,854 - $187,154	-13,641 Reduced 57.87%	9,932 $80,000
Q2 2022 Aug 12, 2022	BUY	$10.22 - $13.94 $130,151 - $177,525	12,735 Added 117.5%	23,573 $274,000
Q1 2022 May 16, 2022	SELL	$5.22 - $11.78 $205,579 - $463,931	-39,383 Reduced 78.42%	10,838 $121,000
Q4 2021 Feb 14, 2022	BUY	$5.37 - $8.38 $85,232 - $133,007	15,872 Added 46.21%	50,221 $327,000
Q3 2021 Nov 09, 2021	BUY	$7.36 - $13.67 $184,986 - $343,581	25,134 Added 272.75%	34,349 $262,000
Q2 2021 Aug 13, 2021	SELL	$8.42 - $13.96 $75,653 - $125,430	-8,985 Reduced 49.37%	9,215 $117,000
Q1 2021 May 13, 2021	SELL	$3.2 - $16.51 $3,561 - $18,375	-1,113 Reduced 5.76%	18,200 $237,000
Q4 2020 Feb 11, 2021	BUY	$2.92 - $4.84 $27,097 - $44,915	9,280 Added 92.49%	19,313 $65,000
Q3 2020 Nov 12, 2020	SELL	$3.03 - $5.48 $6,017 - $10,883	-1,986 Reduced 16.52%	10,033 $39,000
Q2 2020 Aug 12, 2020	BUY	$3.53 - $6.17 $20,766 - $36,298	5,883 Added 95.88%	12,019 $64,000
Q1 2020 May 13, 2020	SELL	$3.53 - $12.21 $43,549 - $150,634	-12,337 Reduced 66.78%	6,136 $26,000
Q4 2019 Feb 10, 2020	BUY	$11.58 - $17.37 $57,749 - $86,624	4,987 Added 36.98%	18,473 $225,000
Q3 2019 Nov 14, 2019	SELL	$13.91 - $19.87 $66,225 - $94,601	-4,761 Reduced 26.09%	13,486 $210,000
Q2 2019 Aug 14, 2019	BUY	$13.19 - $28.36 $37,208 - $80,003	2,821 Added 18.29%	18,247 $266,000
Q1 2019 May 15, 2019	BUY	$12.43 - $28.91 $113,995 - $265,133	9,171 Added 146.62%	15,426 $348,000
Q4 2018 Feb 14, 2019	SELL	$10.57 - $19.29 $183,653 - $335,163	-17,375 Reduced 73.53%	6,255 $75,000
Q3 2018 Nov 14, 2018	BUY	$17.31 - $29.82 $310,229 - $534,434	17,922 Added 313.98%	23,630 $439,000
Q2 2018 Aug 14, 2018	BUY	$6.85 - $38.49 $29,886 - $167,931	4,363 Added 324.39%	5,708 $159,000
Q1 2018 May 15, 2018	BUY	$8.34 - $12.5 $11,217 - $16,812	1,345 New	1,345 $12,000

Others Institutions Holding EOLS

# of Institutions

168

Shares Held

47.8M

Call Options Held

130K

Put Options Held

51K

View Full List

About Evolus, Inc.

Ticker EOLS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 56,094,800
Market Cap $609M
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...

More about EOLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account